Skip to content


    DEA Class; Rx

    Common Brand Names; Navelbine

    • Antineoplastics, Vinca Alkaloid

    Semi-synthetic vinca alkaloid; microtubule inhibitor
    Used for the treatment of metastatic non-small cell lung cancer
    Vesicant; closely monitor for signs and symptoms of extravasation

    Indicated for the treatment of non-small cell lung cancer (NSCLC).

    Indicated for metastatic non-small cell lung cancer (NSCLC)

    Indicated in combination with cisplatin for first-line treatment of locally advanced or metastatic NSCLC

    • Leukopenia (92%)
    • Granulocytopenia (90%)
    • Anemia (83%)
    • Elev AST (67%)
    • Nausea (44%)
    • Asthenia (36%)
    • Constipation (35%)
    • Fatigue (27%)
    • Peripheral neuropathy (25%)
    • Vomiting (20%)
    • Anorexia (20%)
    • Stomatitis (20%)
    • Alopecia (12%)

    Myelosuppression, manifested by neutropenia, anemia, and thrombocytopenia reported; neutropenia is the major dose-limiting toxicity; monitor complete blood counts before each dose

    Risk of extravasation and tissue injury

    Sensory and motor neuropathies reported

    Can cause fetal harm if administered to pregnant women based on findings from animal studies and mechanism of action

    Based on animal findings, can cause fetal harm when administered to pregnant women

    Verify pregnancy status in females of reproductive potential before initiating

    Data are not available regarding drug in human milk or effects on breastfed infant or milk production

    Because of potential harm; advise women not to breastfeed during treatment and for 9 days after final dose


    30 mg/m2 IV.


    30 mg/m2 IV.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.

    Vinorelbine tartrate

    injectable solution

    • 10mg/1mL
    • 50mg/5mL